(Hetland et al. 2010; Gartlehner et al. 2006) Despite the multiplicity of such published trials discussing the efficacy of biologic Tumor necrosis Factor inhibitors in refractory rheumatoid arthritis (RA), studies displaying predictors of good response to such therapy in the daily life clinical practice remain insufficient and heterogeneous demanding continued testing of such predictors within different ethnic populations and at different levels of rheumatology practice (Scott and Kingsley 2006; Taylor and Feldmann 2009; Grewal 2009; Canhão et al. 2012). This evidence concerns the gene TNF and rheumatoid arthritis.